Neuropsychiatric adverse effects of Mefloquine: What do we know and what should we do?

CNS Drugs

Volumn 11, Issue 1, 1999, Pages 1-8

  Nosten, François ^a,b,c   Van Vugt, Michele ^a,b,d  

^a SHOKLO MALARIA RESEARCH UNIT   (Thailand)

^b MAHIDOL UNIVERSITY   (Thailand)

^c JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

MEFLOQUINE;

AFFECTIVE NEUROSIS; CLINICAL TRIAL; DRUG RESISTANCE; HEADACHE; HUMAN; MALARIA; MALARIA CONTROL; MENTAL DISEASE; NEUROLOGIC DISEASE; NEUROPATHY; NEUROSIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SEIZURE; VERTIGO;

EID: 0032901418     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-199911010-00001     Document Type: Review

References (48)

1. 1. Nosten F, van Vugt M. Malaria, still no vaccine and very few drugs. Curr Opin Infect Dis 1996; 9: 429-34
2. 2. Paris L, Caumes E, Bustos M, et al. Resistance of Plasmodium falciparum to mefloquine in Sierra Leone and Kenya [letter]. Presse Med 1990; 19 (27): 1283
3. 3. Nosten F, Luxemburger C, ter Kuile F, et al. Treatment of multi-drug-resistant Plasmodium falciparum malaria with 3-day artesunate-mefloquine combination. J Infect Dis 1994; 170 (4): 971 -7
4. 4. White NJ. Mefloquine [editorial]. BMJ 1994; 308 (6924): 286-7
5. 5. Palmer KJ, Holliday SM, Brogden RN. Mefloquine. A review of its antimalarial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1993; 45 (3): 430-75
6. 6. Lobel HO, Keystone JS. Confusion on malaria chemoprophylaxis [letter]. Lancet 1994; 343 (8890): 183
7. 7. Cook GC. Malaria prophylaxis. Mefloquine toxicity should limit its use to treatment alone [letter]. BMJ 1995; 311 (6998): 190-1
8. 8. CIOMS International reporting of adverse drug reactions. CIOMS Working Group Report. Geneva: World Health Organization, 1997
9. 9. World Health Organization. Review of central nervous system adverse events related to the antimalarial drug mefloquine (1985-1990). WHO/MAL/91.1063. Geneva: World Health Organization, 1991
10. 10. Lobel HO, Miani M, Eng T, et al. Long-term malaria prophylaxis with weekly mefloquine. Lancet 1993; 341 (8849): 848-51
11. 11. Hoebe C, de MJ, Thijs C. Side effects and compliance with mefloquine or proguanil antimalarial chemoprophylaxis. Eur J Clin Pharmacol 1997; 52 (4): 269-75
12. 12. Steffen R, Fuchs E, Schildknecht J, et al. Mefloquine compared with other malaria chemoprophylactic regimens in tourists visiting east Africa. Lancet 1993; 341 (8856): 1299-303
13. 13. Barrett PJ, Emmins PD, Clarke PD, et al. Comparison of adverse events associated with use of mefloquine and combination of chloroquine and proguanil as antimalarial prophylaxis: postal and telephone survey of travelers. BMJ 1996; 313 (7056): 525-8
14. 14. Carme B, Peguet C, Nevez G. Compliance with and tolerance of mefloquine and chloroquine + proguanil malaria chemoprophylaxis in French short-term travellers to sub-Saharan Africa. Trop Med Int Health 1997; 2 (10): 953-6
15. 15. Sanchez JL, DeFraites RF, Sharp TW, et al. Mefloquine or doxycycline prophylaxis in US troops in Somalia [letter]. Lancet 1993; 341 (8851): 1021-2
16. 16. Davis TM, Dembo LG, Kaye-Eddie SA, et al. Neurological, cardiovascular and metabolic effects of mefloquine in healthy volunteers: a double-blind, placebo-controlled trial. Br J Clin Pharmacol 1996; 42 (4): 415-21
17. 17. Riemsdijk van RM, van der Klauw MM, van HJ, et al. Neuropsychiatric effects of antimalarials. Eur J Clin Pharmacol 1997; 52 (1): 1-6
18. 18. Croft AM, Clayton TC, World MJ. Side effects of mefloquine prophylaxis for malaria: an independent randomized controlled trial. Trans R Soc Trop Med Hyg 1997; 91 (2): 199-203
19. 19. Arthur JD, Shanks GD, Echeverria P. Mefloquine prophylaxis [letter]. Lancet 1990; 335 (8695): 972
20. 20. Schlagenhauf P, Steffen R, Lobel H, et al. Mefloquine tolerability during chemoprophylaxis: focus on adverse event assessments, stereochemistry and compliance. Trop Med Int Health 1996; 1 (4): 485-94
21. 21. Nosten F, Karbwang J, White NJ, et al. Mefloquine antimalarial prophylaxis in pregnancy: dose finding and pharmacokinetic study. Br J Clin Pharmacol 1990; 30 (1): 79-85
22. 22. Bunnag D, Malikul S, Chittamas S, et al. Fansimef for prophylaxis of malaria: a double-blind randomized placebo controlled trial. Southeast Asian J Trop Med Public Health 1992; 23 (4): 777-82
23. 23. Ohrt C, Richie TL, Widjaja H, et al. Mefloquine compared with doxycycline for the prophylaxis of malaria in Indonesian soldiers. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1997; 126 (12): 963-72
24. 24. Salako LA, Adio RA, Walker O, et al. Mefloquine-sulphadoxine-pyrimethamine (Fansimef, Roche) in the prophylaxis of Plasmodium falciparum malaria: a double-blind, comparative, placebo-controlled study. Ann Trop Med Parasitol 1992; 86 (6): 575-81
25. 25. Bem JL, Kerr L, Stuerchler D. Mefloquine prophylaxis: an overview of spontaneous reports of severe psychiatric reactions and convulsions. J Trop Med Hyg 1992; 95 (3): 167-79
26. 26. Boudreau E, Schuster B, Sanchez J, et al. Tolerability of prophylactic Lariam regimens. Trop Med Parasitol 1993; 44 (3): 257-65
27. 27. Sturchler D, Handschin J, Kaiser D, et al. Neuropsychiatric side effects of mefloquine [letter]. N Engl J Med 1990; 322 (24): 1752-3
28. 28. Le NN, De VP, Le TD, et al. Single dose artemisinin-mefloquine versus mefloquine alone for uncomplicated falciparum malaria. Trans R Soc Trop Med Hyg 1997; 91 (2): 191-4
29. 29. Croft A, Garner P. Mefloquine to prevent malaria: a systematic review of trials. BMJ 1997; 315 (7120): 1412-6
30. 30. Behrens RH, Erny S, Maradit H, et al. Mefloquine to prevent malaria [letters]. BMJ 1998; 7149: 1980-1
31. 31. Hopperus Buma APCC, van Thiel PPAM, Lobel HO, et al. Long-term malaria chemoprophylaxis with mefloquine in Dutch marines in Cambodia. J Infect Dis 1996; 173: 1506-9
32. 32. Phillips-Howard PA, ter Kuile F. CNS adverse events associated with antimalarial agents: fact or fiction? Drug Saf 1995; 12 (6): 370-83
33. 33. Vuurman EF, Muntjewerff ND, Uiterwijk MM, et al. Effects of mefloquine alone and with alcohol on psychomotor and driving performance. Eur J Clin Pharmacol 1996; 50 (6): 475-82
34. 34. Wittes RC, Saginur R. Adverse reaction to mefloquine associated with ethanol ingestion. Can Med Assoc J 1995; 152 (4): 515-7
35. 35. Winstanley P. Mefloquine: the benefits outweigh the risks. Br J Clin Pharmacol 1996; 42 (4): 411-3
36. 36. Sowunmi A, Salako LA, Oduola AM, et al. Neuropsychiatric side effects of mefloquine in Africans. Trans R Soc Trop Med Hyg 1993; 87 (4): 462-3
37. 37. Luxemburger C, Nosten F, ter Kuile F, et al. Mefloquine for multidrug-resistant malaria [letter]. Lancet 1991; 338: 1268
38. 38. ter Kuile F. Mefloquine, halofantrine and artesunate in the treatment of uncomplicated falciparum malaria in a multidrug resistant area [PhD thesis]. Amsterdam: University of Amsterdam, 1994
39. 39. Nguyen TH, Day NP, Ly VC, et al. Post-malaria neurological syndrome. Lancet 1996; 348 (9032): 917-21
40. 40. Luxemburger C, Price RN, Nosten F, et al. Mefloquine in infants and young children. Ann Trop Paediatr 1996; 16 (4): 281-6
41. 41. McGready R, Cho T, Hkirijaroen L, et al. Quinine and mefloquine in the treatment of multidrug-resistant Plasmodium falciparum in pregnancy. Ann Trop Med Parasit 1998; 92 (6): 643-53
42. 42. Looareesuwan S, Wilairatana P, Molunto W, et al. A comparative clinical trial of sequential treatments of severe malaria with artesunate suppository followed by mefloquine in Thailand. Am J Trop Med Hyg 1997; 57 (3): 348-53
43. 43. Jones R, Kunsman G, Levine B, et al. Mefloquine distribution in postmortem cases. Forensic Sci Int 1994; 68 (1): 29-32
44. 44. Pham YT, Nosten F, Farinotti R, et al. Cerebral uptake of mefloquine enantiomers in fatal cerebral malaria. Int J Clin Pharmacol. In press
45. 45. Speich R, Haller A. Central anticholinergic syndrome with the antimalarial drug mefloquine [letter]. N Engl J Med 1994; 331 (1): 57-8
46. 46. Petersen E, Hogh B, Bygbjerg IC, et al. Malaria chemoprophylaxis: why mefloquine? [letter]. Lancet 1990; 336 (8718): 811
47. 47. Behrens RH, Bradley DJ, Snow RW, et al. Impact of UK malaria prophylaxis policy on imported malaria [letter]. Lancet 1996; 348 (9023): 344-5
48. 48. CDR Review - Communicable Disease Report 1997; 10: 137-152